viewAmphion Innovations PLC

Amphion Innovations boss doubles his stake

Chief executive Richard Morgan now owns 23.7% of Amphion’s issued share capital after purchasing 26mln shares from the estate of a former chairman

Amphion Innovations PLC -
On Monday, Amphion sold its stake in medical imaging business Polarean Imaging PLC for total proceeds of US$2.6mln

Amphion Innovations PLC’s (LON:AMP) chief executive has bumped up stake in the tech and medical business development group up to 23.7%, as it ramps up efforts to pay down debts with a view to resuming trading on AIM.

In an update on Wednesday, the company said its CEO Richard Morgan had purchased 26mln shares directly from the wife of former chairman James Macaleer for US$100.

READ: Amphion no longer holds any shares in Polarean Imaging

Following the purchase, Morgan owns 23.7% of Amphion’s issued share capital.

The company it was in “advanced discussions” to settle approximately US$10mln in debt owed to the Macaleer Estate.

With Amphion's currently suspended shares resume trading, Morgan will pay Macaleer an additional US$25,000 for Wednesday’s purchase. 

On Monday, Amphion, still “highly cash constrained” as it explored options to pay down its debts, sold its stake in medical imaging business Polarean Imaging PLC for US$2.6mln.

Under AIM rules this “fundamental disposal” means Amphion is now required by London Stock Exchange to either complete a reverse takeover or be re-admitted to trading as an investing company, requiring a fundraise of at least US$6mln.

Quick facts: Amphion Innovations PLC

Price: - -

Market: AIM
Market Cap: -

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Amphion Innovations PLC named herein, including the promotion by the Company of Amphion Innovations PLC in any Content on the Site, the Company...


Amphion Innovations pinning hopes on Polarean Inc after Motif Bio success

Richard Morgan, chief executive of Amphion PLC (LON:AMP), discusses the 'very welcome' Phase III Iclaprim news from Motif Bio. Motif's recently revealed its lead drug, a next generation antibiotic, successfully negotiated a crucial final-stage clinical study, boosting Amphion’s...

on 10/10/17

2 min read